Sign in
CompletedPhase 2

A randomized, double-blind, placebo-controlled dose-finding study of 0.05%, 0.025%, 0.01% and 0.005% atropine eye drops to inhibit myopia progression in children in a European population

Key facts

Who runs it
Pharma Stulln GmbH
Where
Germany4 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
135 people enrolled
Started
19 Sept 2022
Ended
15 Apr 2025
Type of study
Interventional
Record updated
9 December 2024

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Male subjects and female subjects from 6 to 12 years of age. (female subjects who cannot become pregnant and female subjects of child bearing potential (after menarche) who use an highly effective contraceptive method or strategy (failure rate per year < 1%) according to the CTFG Guidance "Recommendations related to contraception and pregnancy testing in clinical trials, version 1.1, updated"; see Section 11.3)
  • Subjects showing myopia between ≥-1.0 and ≤-4.0 D (spherical equivalent as assessed by autorefraction under cycloplegia) and a progression of myopia within the past 12 months in at least one eye
  • Parents or legal guardians who have been informed about the clinical study and have signed the informed consent form

Who cannot take part

  • Previous or current alcohol or drug abuse
  • History of any myopia treatment within 3 months before inclusion: e.g. DIMS glasses, Orthokeratology contact lenses, multifocal contact lenses, atropine eye drops
  • Known intolerances to atropine eye drops or known hypersensitivity to any of the other components of the investigational product, allergies against eye drops
  • Presence of a contraindication for the treatment with atropine: - Hypersensitivity to the active substance or to any of the excipients. - Primary forms of glaucoma - narrow-angle glaucoma - rhinitis sicca - Narrow-angel of anterior chamber - Tachycardia, congestive heart failure, coronary stenoses - Thyrotoxicosis, hyperthyroidism - Mechanical obstruction of the gastrointestinal tract - Paralytic ileus - Megacolon - Obstructive urinary tract diseases, e.g. prostatic hypertrophy with residual urine formation - Myasthenia gravis - Acute pulmonary edema - Pregnancy toxicosis - Spastic paralysis
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 10. Treatment with sympathomimetics
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 8. Any ocular therapy other than the IMP, except for antibiotic or antiallergic eye drops
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 9. Treatments with - Monoamine oxidase (MAO) inhibitor therapy - Antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserine)
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 11. Treatment with drugs that may increase the anticholinergic effect of atropine: - Amantadine - Anti-arrhymics such as chinidine, procainamide and disopyramide - Dopamine-antagonists such as metoclopramide - Antihistaminics - Certain anti-Parkinsonian drugs (except dopamine receptor agonists) - Neuroleptics
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 12. Treatment with pilocarpin and physostigmine containing drugs
  • Concomitant Therapy within the last 3 Months prior to Enrollment:13. Treatment with digoxine and nitrofurantoin
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 14. Treatment with phenothiazine
  • Concomitant Therapy within the last 3 Months prior to Enrollment: 15. Treatment with levodopa
  • Down syndrome
  • Anisometropia (SE) > |1.0| D
  • Mental or emotional instability of the subject, parents or legal guardians that might jeopardize the validity of the informed consent or the compliance with the study procedures
  • Corneal astigmatism (ΔTK) > |1.5| D
  • Unreliability or lack of cooperation
  • Pregnancy
  • Best corrected visual acuity VADecimal< 1.0 (VAlogMAR > 0.0)
  • Pathological findings in the eyes, i.e. pathological myopia, corneal scars and pathologies in the anterior or posterior segments of the eye
  • Other reasons why, in the opinion of the investigator, the subjects should not participate in the study
  • Enrolment in another clinical study within the last 4 weeks or during enrolment in this study
  • East Asian or African origin

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the optimal dose of low-dose atropine eye drops compared to placebo for the inhibition of myopia progression in children

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
9 December 2024